**Author details**

Rajalakshmi Manikkam\* and Indu Sabapathy Department of Biotechnology and Bioinformatics, Holy Cross College (Autonomous), Tamil Nadu, India

\*Address all correspondence to: mdraji@gmail.com

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**171**

*Combinatorial Drug Therapy with Phytochemicals as Adjuvants in Prostate Cancer Management*

[10] Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. Journal

of Carcinogen. 2011;**10**:20

[11] Ross RK, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B. Serum testosterone levels in healthy young black and white men. Journal of the National Cancer Institute. 1986;**76**:45-48

[12] Quayle SN, Mawji NR, Wang J, Sadar MD. Androgen receptor decoy molecules block the growth of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 2007;**104**:1331-1336

[13] Kasper S, Cookson MS. Mechanisms

hormone-resistant prostate cancer. The Urologic Clinics of North America.

[15] Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Research. 1994;**54**:5474-5478

[16] Srinivasan SR, Freedman DS, Sundaram GS, Webber LS, Berenson GS. Racial (black-white) comparisons

[17] Chen M, Ni J, Chang HC, Lin CY, Muyan M, Yeh S. CCDC62/ERAP75 functions as a coactivator to enhance

of the relationship of levels of endogenous sex hormones to serum lipoproteins during male adolescence, the Bogalusa heart study. Circulation.

1986;**74**:1226-1232

leading to the development of

[14] Edwards J, Bartlett JM. The androgen receptor and signal transduction pathways in hormonerefractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU International.

2006;**33**:201-210

2005;**95**:1327-1335

*DOI: http://dx.doi.org/10.5772/intechopen.86157*

[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: A Cancer Journal

for Clinicians. 2015;**65**:87-108

Journal of Epidemiology.

Research. 2007;**175**:33-63

1995;**75**:1823-1836

2004;**17**:292-306

Urology. 2011;**59**:61-71

1989;**142**:326-331

2008;**37**:147-160

[2] Rastogi T, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R, et al. Cancer incidence rates among south Asians in four geographic regions: India, Singapore, UK and US. International

[3] Novara G, Galfano A, Berto RB, Ficarra V, Navarrete RV, Artibani W. Inflammation, apoptosis, and BPH: What is the evidence. European Association of Urology. 2006;**5**:401-409

[4] Griffiths K, Prezioso D, Turkes A, Denis LJ. The prevention of prostate cancer. Recent Results in Cancer

[5] Bostwick DG. High-grade prostatic intraepithelial neoplasia: The most likely precursor of prostate cancer. Cancer.

[6] Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Modern Pathology.

[7] Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part I: Screening, diagnosis, and treatment of clinically localised disease. European

[8] Kabalin JN, Hodge KK, McNeal JE, Freiha FS, Stamey TA. Identification of residual cancer in the prostate following radiation therapy: Role of transrectal ultrasound guided biopsy and prostate specific antigen. The Journal of Urology.

[9] Mc Neal JE. The prostate gland: Morphology and pathophysiology. Monograph Urology. 1983;**4**:3-12

**References**

*Combinatorial Drug Therapy with Phytochemicals as Adjuvants in Prostate Cancer Management DOI: http://dx.doi.org/10.5772/intechopen.86157*
